NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zogenix Inc (NASDAQ: ZGNX)

 
ZGNX Technical Analysis
5
As on 7th Mar 2022 ZGNX STOCK Price closed @ 26.68 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 19.00 & Strong Buy for SHORT-TERM with Stoploss of 20.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZGNXSTOCK Price

Open 26.68 Change Price %
High 26.68 1 Day 0.00 0.00
Low 26.68 1 Week 0.52 1.99
Close 26.68 1 Month 0.70 2.69
Volume N/A 1 Year 9.10 51.76
52 Week High 26.68 | 52 Week Low 11.25
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
APTO 0.28 64.71%
NVDA 134.70 3.08%
TNXP 0.61 7.02%
LCID 3.02 14.83%
TAOP 0.41 28.12%
AVGO 220.79 1.13%
TSLA 421.06 -3.46%
QUBT 17.62 16.38%
AAPL 254.49 1.88%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
MYSZ 4.25 214.81%
MYSZ 4.25 214.81%
NDRAW 0.03 200.00%
IMAQW 0.03 200.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
TSCO 53.92 -79.58%
TSCO 53.92 -79.58%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
TFFP 0.06 -62.50%
PRFX 5.02 -55.38%
MTEM 0.16 -54.29%
 
 
ZGNX
Daily Charts
ZGNX
Intraday Charts
Whats New @
Bazaartrend
ZGNX
Free Analysis
 
ZGNX Important Levels Intraday
RESISTANCE26.68
RESISTANCE26.68
RESISTANCE26.68
RESISTANCE26.68
RESISTANCE26.68
RESISTANCE26.68
RESISTANCE26.68
RESISTANCE26.68
 
ZGNX Forecast December 2024
4th UP Forecast34.97
3rd UP Forecast32.31
2nd UP Forecast30.67
1st UP Forecast29.02
1st DOWN Forecast24.34
2nd DOWN Forecast22.69
3rd DOWN Forecast21.05
4th DOWN Forecast18.39
 
ZGNX Weekly Forecast
4th UP Forecast32.23
3rd UP Forecast30.45
2nd UP Forecast29.35
1st UP Forecast28.25
1st DOWN Forecast25.11
2nd DOWN Forecast24.01
3rd DOWN Forecast22.91
4th DOWN Forecast21.13
 
ZGNX Forecast2024
4th UP Forecast57.26
3rd UP Forecast47.45
2nd UP Forecast41.39
1st UP Forecast35.33
1st DOWN Forecast18.03
2nd DOWN Forecast11.97
3rd DOWN Forecast5.91
4th DOWN Forecast-3.9
 
 
ZGNX Other Details
Segment EQ
Market Capital 846850112.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZGNX Address
ZGNX
 
ZGNX Latest News
 
Your Comments and Response on Zogenix Inc
 
ZGNX Business Profile
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California. Address: 5959 Horton Street, EmeryVille, CA, United States, 94608
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service